ESR1 and breast carcinoma: Ki67 IHC is a useful tool in assessing the risk of recurrence for ER-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, where it may be considered a surrogate of molecular assays for distinguishing luminal A from luminal B breast cancer subtypes.